InVitae Corp (NASDAQ: NVTA) and Digiliti Money (NASDAQ:DGLT) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitabiliy, institutional ownership, valuation and analyst recommendations.
Institutional and Insider Ownership
4.8% of Digiliti Money shares are held by institutional investors. 50.9% of Digiliti Money shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
This table compares InVitae Corp and Digiliti Money’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares InVitae Corp and Digiliti Money’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|InVitae Corp||$31.43 million||12.43||-$95.64 million||N/A||N/A|
|Digiliti Money||$9.03 million||0.40||-$6.89 million||N/A||N/A|
Digiliti Money has higher revenue, but lower earnings than InVitae Corp.
This is a summary of current recommendations and price targets for InVitae Corp and Digiliti Money, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
InVitae Corp currently has a consensus price target of $14.00, indicating a potential upside of 51.68%. Digiliti Money has a consensus price target of $6.00, indicating a potential upside of 1,521.62%. Given Digiliti Money’s higher probable upside, analysts plainly believe Digiliti Money is more favorable than InVitae Corp.
Digiliti Money beats InVitae Corp on 6 of the 10 factors compared between the two stocks.
About InVitae Corp
Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. As of December 31, 2016, the Company’s products consisted of assays totaling over 1,100 genes that could be used for multiple indications, including hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders and other hereditary conditions. The Company offers panels for a range of hereditary conditions in cancer, cardiology, neuromuscular, pediatric and rare diseases. The Company focuses on genetic testing, genome network and genome management. The Company offers full gene sequencing and deletion/duplication analysis as a standard for all of its tests. The Company holds interests in AltaVoice, a patient-centered data company.
About Digiliti Money
Digiliti Money Group, Inc., formerly Digiliti Money, Inc., is a technology solutions and services provider to the financial services industry. The Company’s solutions and services enable its clients, such as banks, credit unions and alternative financial services providers (AFS) to offer their customers remote deposit capture (RDC) and prepaid mobile money technologies and related services. It offers RDC products for businesses and consumers; mobile money management products for consumers, and training and support services for its financial services industry customers. The RDC products are offered to banks and credit unions in the United States, Canada and Latin America. Its mobile money management products are offered to traditional financial institutions (FIs), as well as AFS in the United States, Canada and Latin America. These FIs and AFS providers include banks, credit unions, prepaid card issuers, check cashers and payday lenders.
Receive News & Ratings for InVitae Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae Corp and related companies with our FREE daily email newsletter.